Simon Eade is Global Therapeutic Area Head of Commercial Strategy for Pulmonary Hypertension (PH). His team collaborates with the major markets to set the strategy for each brand and deliver key marketing, reimbursement, and commercial tools to ensure that brands quickly find their way to patients.
In previous roles, Simon served as Vice President and Head of the Northern European Region and Vice President and Head of the Asia Pacific Region, where he extended Actelion’s reach and the availability of its key orphan drugs across Asia (excluding Japan). Simon also led the commercial strategy development and launch for OPSUMIT® (macitentan) and VELETRI® (iv. epospotonol). He oversaw the pre-launch work on a variety of additional Actelion compounds across multiple disease areas, including UPTRAVI® (selexipag). In 2002, he helped establish the UK and Ireland affiliate where Actelion launched TRACLEER® and ZAVESCA®.
Before joining Actelion, Simon worked at both Novartis and Serono. In all, he has spent almost two decades focusing on the area of orphan drugs, helping develop awareness for conditions like pulmonary arterial hypertension (PAH), driving medical education to improve diagnosis, and finding ways to enhance access to novel therapies.